In response to queries from The Edge Singapore, Mirxes said that it "would like to emphasise" that it was not the source for Bloomberg article, adding that the article has cited other sources.
Singapore biotechnology startup Mirxes has denied that it has any formal IPO plans in Singapore, contradicting an earlier Bloomberg report.
On June 27, Bloomberg reported the company was weighing an IPO in Singapore next year that could raise about US$300 million ($415.7 million), citing "people with knowledge of the matter."
